Ftse Mib
34.460,52
0,00%
DAX
18.680,20
-0,25%
S&P 500
5.307,01
-0,27%
NASDAQ
16.801,54
-0,18%
Bitcoin
69.453,53
0,51%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Milestone Pharmaceuticals Inc (MIST) Milestone Pharmaceuticals Inc (MIST) Notizie

MIST

Milestone Pharmaceuticals (MIST)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MIST
DataOraFonteTitoloSimboloCompagnia
22/05/202414:00GlobeNewswire Inc.Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT AwarenessNASDAQ:MISTMilestone Pharmaceuticals Inc
13/05/202413:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
13/05/202412:59Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MISTMilestone Pharmaceuticals Inc
01/03/202422:52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MISTMilestone Pharmaceuticals Inc
29/02/202413:00GlobeNewswire Inc.Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
28/02/202422:37GlobeNewswire Inc.Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
15/02/202402:56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202314:54Dow Jones NewsMilestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDANASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202313:57Dow Jones NewsMilestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File LetterNASDAQ:MISTMilestone Pharmaceuticals Inc
21/11/202313:00PR Newswire (Canada)Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202312:57PR Newswire (Canada)Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNASDAQ:MISTMilestone Pharmaceuticals Inc
11/11/202316:00PR Newswire (US)Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
09/11/202322:43Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:MISTMilestone Pharmaceuticals Inc
07/11/202313:00PR Newswire (US)Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVRNASDAQ:MISTMilestone Pharmaceuticals Inc
24/10/202313:00PR Newswire (US)Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for EtripamilNASDAQ:MISTMilestone Pharmaceuticals Inc
06/10/202313:00PR Newswire (US)Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MISTMilestone Pharmaceuticals Inc
27/09/202313:00PR Newswire (US)Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
05/09/202313:00PR Newswire (US)Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
10/08/202313:35PR Newswire (Canada)Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate UpdateNASDAQ:MISTMilestone Pharmaceuticals Inc
20/06/202313:00PR Newswire (US)Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The LancetNASDAQ:MISTMilestone Pharmaceuticals Inc
09/06/202322:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MISTMilestone Pharmaceuticals Inc
01/06/202313:00PR Newswire (Canada)Milestone Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
31/05/202312:02Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:MISTMilestone Pharmaceuticals Inc
30/05/202312:07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MISTMilestone Pharmaceuticals Inc
22/05/202313:00PR Newswire (Canada)Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular RateNASDAQ:MISTMilestone Pharmaceuticals Inc
15/05/202323:22Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:MISTMilestone Pharmaceuticals Inc
11/05/202313:25Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MISTMilestone Pharmaceuticals Inc
11/05/202313:16PR Newswire (US)Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate UpdateNASDAQ:MISTMilestone Pharmaceuticals Inc
08/05/202313:00PR Newswire (Canada)Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular RateNASDAQ:MISTMilestone Pharmaceuticals Inc
28/04/202323:22Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MISTMilestone Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MIST

La tua Cronologia

LSE
SK27
Chile.29
LSE
QT25
Morg.st.b.v 24
BIT
F13733
Vontobel Financial Produ...
UNSW3
TCFXUSDT
Tcbcoin
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network